IPHARMA was authorized to conduct a Phase IIa clinical trial

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase IIa clinical trial of the drug Istaroxime (PST2744) (Windtree Therapeutics, Inc.).

Protocol № 04-CL-1904 "A multicenter randomized double-blind placebo-controlled parallel group study on the safety and efficacy of Istaroxime in patients with pre-cardiogenic shock (SEISMiC)".

The study will be conducted in healthcare facilities of Moscow.


Недавние посты

© 2021 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon